к⎧ሿᯩࡦ㦟㛑ԭᴹ䲀ޜਨ ֯⭘䜘࠶Ჲᰦ䰢㖞ए䳶䍴䠁䘋㹼⧠䠁㇑⨶һ亩ⲴṨḕ㿱 ഭؑ䇱ࡨ㛑ԭᴹ䲀ޜਨޣҾ ޜᔰਁ㹼Ӫ≁ᐱᲞ䙊㛑˄$ 㛑˅㛑⾘˄ԕлㆰ〠³ᵜ⅑ਁ㹼´˅ з㛑ˈ⇿㛑 ਁ㹼ԧṬѪӪ≁ᐱ ݳˈए䳶䍴䠁ᙫ仍ѪӪ≁ᐱ ݳˈᢓ䲔亩 ਁ㹼䍩⭘ਾए䳶䍴䠁߰仍ѪӪ≁ᐱ ݳˈԕкए䳶䍴䠁ᐢ㓿Პॾ≨ 䚃ѝཙՊ䇑ᐸһ࣑ᡰ˄⢩↺Პ䙊ਸՉ˅Ҿ ᒤ ᴸ ᰕࠪާⲴ³Პॾ≨䚃ѝ ཙ傼ᆇ˄˅ㅜ ਧ´lj傼䍴ᣕNJᇑ傼⺞䇔DŽ ए䳶䍴䠁ࡠ䍖ਾˈѪ㿴㤳ए䳶䍴䠁㇑⨶઼֯⭘ˈ؍ᣔᣅ䍴㘵ᵳ⳺ˈޜਨо؍ 㦀ᵪᶴ৺ᆈ᭮ए䳶䍴䠁Ⲵ୶ъ䬦㹼ㆮ㖢Ҷljए䳶䍴䠁йᯩⴁ㇑ॿ䇞NJˈᔰ䇮Ҷए 䳶䍴䠁у亩䍖ᡧˈሩए䳶䍴䠁ᇎ㹼уᡧᆈۘDŽ ഭؑ䇱ࡨ㛑ԭᴹ䲀ޜਨ˄ԕлㆰ〠Ā؍㦀ᵪᶴā˅Ѫк⎧ሿᯩࡦ㦟㛑ԭᴹ 䲀ޜਨ˄ԕлㆰ〠Āሿᯩࡦ㦟āᡆĀޜਨā˅俆⅑ޜᔰਁ㹼㛑⾘ᒦкᐲⲴ؍㦀ᵪ ᶴˈṩᦞlj䇱ࡨਁ㹼кᐲ؍㦀ъ࣑⨶㇑࣎⌅NJljкᐲޜਨए䳶䍴䠁ⴁ㇑㿴ࡉNJljк ⎧䇱ࡨӔ᱃ᡰ㛑⾘кᐲ㿴ࡉNJljк⎧䇱ࡨӔ᱃ᡰкᐲޜਨ㠚ᖻⴁ㇑ᤷᕅㅜ ਧü ü㿴㤳䘀NJㅹᴹޣ㿴ᇊˈሩሿᯩࡦ㦟֯⭘䜘࠶Ჲᰦ䰢㖞ए䳶䍴䠁䘋㹼⧠䠁㇑⨶ һ亩䘋㹼ҶᇑṨḕˈާփṨḕᛵߥྲл˖ аǃᣅ䍴ᛵߥᾲ䘠 ˄а˅ ...

Financial Performance - The company's revenue for Q3 2025 reached ¥127,428,922.73, an increase of 20.87% compared to the same period last year[4]. - The total profit for the period was ¥56,933,271.87, reflecting a growth of 14.24% year-over-year[4]. - The net profit attributable to shareholders was ¥49,072,717.48, up by 14.51% from the previous year[4]. - The net profit for the first three quarters of 2025 reached CNY 169,893,968.80, an increase from CNY 161,669,487.31 in the same period of 2024, representing a growth of approximately 13.5%[20]. - Operating profit for the same period was CNY 198,450,191.52, compared to CNY 189,081,288.34 in 2024, indicating a year-over-year increase of about 7.3%[20]. - The company reported sales revenue from goods and services of CNY 416,771,775.69, compared to CNY 406,134,600.13 in the previous year, reflecting a growth of about 2.0%[22]. - The total comprehensive income for the period was CNY 169,893,968.80, compared to CNY 161,669,487.31 in 2024, showing an increase of approximately 5.4%[21]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was ¥133,936,717.80, showing a decline of 20.12% compared to the previous year[4]. - Cash flow from operating activities generated a net amount of CNY 133,936,717.80, down from CNY 167,668,964.18 in the previous year, reflecting a decrease of approximately 20.2%[23]. - The cash flow from financing activities showed a net outflow of CNY 235,851,204.77, contrasting with a net inflow of CNY 463,327,854.95 in the same period last year[24]. - The company ended the period with cash and cash equivalents of CNY 412,565,553.40, down from CNY 552,013,365.43 at the end of the previous year, a decrease of about 25.3%[24]. - Cash and cash equivalents as of September 30, 2025, amounted to ¥734,868,351.75, down from ¥883,430,759.69 at the end of 2024[14]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,307,629,743.16, a decrease of 6.76% from the end of the previous year[5]. - Total assets decreased from ¥1,402,448,475.00 in 2024 to ¥1,307,629,743.16 in 2025, a decline of 6.8%[15]. - Total liabilities increased from ¥168,213,793.02 in 2024 to ¥253,534,342.28 in 2025, reflecting a rise of 50.8%[16]. - Shareholders' equity attributable to the company was ¥1,054,095,400.88, down 14.60% compared to the previous year[5]. - Shareholders' equity decreased from ¥1,234,234,681.98 in 2024 to ¥1,054,095,400.88 in 2025, a decline of 14.6%[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,356[10]. - The largest shareholder, 运佳远东有限公司, holds 58.59% of the shares, totaling 94,080,000 shares[11]. Operating Costs and Expenses - Total operating revenue for the first three quarters of 2025 reached ¥397,218,590.16, an increase of 8.5% compared to ¥367,213,945.74 in the same period of 2024[19]. - Total operating costs for the first three quarters of 2025 were ¥198,287,211.92, up from ¥179,224,454.99 in 2024, reflecting a growth of 10.5%[19]. - Operating costs specifically increased from ¥125,382,134.24 in 2024 to ¥132,124,401.09 in 2025, indicating a rise of 5.9%[19]. - Research and development expenses decreased to CNY 9,124,036.50 from CNY 10,672,621.35, a reduction of approximately 14.5%[20]. Government Subsidies - The company received government subsidies amounting to ¥54,924.12 during the period, contributing to its non-recurring gains[7]. Earnings Per Share - Basic earnings per share for the period stood at ¥0.31, with a year-to-date figure of ¥1.06, down 17.19%[5]. - The basic earnings per share for the current period was CNY 1.06, down from CNY 1.28 in the previous year, indicating a decline of about 17.2%[21].

小方制药10月24日公告，2025年第三季度实现营业收入1.27亿元，同比增长20.87%；归属于上市公司股 东的净利润4907.27万元，同比增长14.51%；基本每股收益0.31元。前三季度实现营业收入3.97亿元，同 比增长8.17%；归属于上市公司股东的净利润1.7亿元，同比增长5.09%；基本每股收益1.06元。 ...

Core Insights - On October 17, Xiaofang Pharmaceutical experienced a decline of 0.80% with a trading volume of 75.57 million yuan [1] - The company reported a financing buy-in amount of 13.82 million yuan and a net financing buy of 3.20 million yuan on the same day [1] - As of October 17, the total financing and securities lending balance for Xiaofang Pharmaceutical reached 112 million yuan, which is 6.13% of its market capitalization [1] Financing Summary - On October 17, Xiaofang Pharmaceutical had a financing buy-in of 13.82 million yuan, with a current financing balance of 112 million yuan, exceeding the 70th percentile of the past year [1] - The company had no securities lending activity on October 17, with a securities lending balance of 0 yuan, indicating a high level of inactivity in this area [1] Business Performance - As of September 19, the number of shareholders for Xiaofang Pharmaceutical was 13,500, a decrease of 8.81% from the previous period [2] - For the first half of 2025, the company achieved a revenue of 270 million yuan, representing a year-on-year growth of 3.06%, and a net profit of 121 million yuan, with a growth of 1.69% [2] - Since its A-share listing, Xiaofang Pharmaceutical has distributed a total of 353 million yuan in dividends [2] Shareholder Composition - As of June 30, 2025, the top ten circulating shareholders included new entrants such as CITIC Jiantou Rotation Mixed A and CITIC Jiantou Selection Mixed A, holding 439,400 shares and 298,100 shares respectively [2] - The fifth largest shareholder, Taixin Leading Strategy Mixed, maintained its holding of 256,800 shares, while Taixin Industry Selection Mixed A exited the top ten list [2]

Summary of Key Points Core Viewpoint - The financial performance and stock activity of Xiaofang Pharmaceutical indicate a stable growth trajectory, with a slight increase in revenue and net profit, while also showing significant activity in financing and stockholder changes [1][2][3]. Financing and Stock Activity - On October 16, Xiaofang Pharmaceutical's stock rose by 0.45%, with a trading volume of 63.32 million yuan. The financing buy-in amount was 4.39 million yuan, while the financing repayment was 13.88 million yuan, resulting in a net financing buy of -9.49 million yuan [1]. - As of October 16, the total financing and securities balance for Xiaofang Pharmaceutical was 108 million yuan, accounting for 5.90% of its market capitalization, which is above the 60th percentile level over the past year [1]. - The company had no short-selling activity on October 16, with a short-selling balance of 0.00 shares, indicating a high level of short-selling availability compared to the past year [1]. Financial Performance - For the first half of 2025, Xiaofang Pharmaceutical reported a revenue of 270 million yuan, representing a year-on-year growth of 3.06%. The net profit attributable to shareholders was 121 million yuan, reflecting a growth of 1.69% [2]. - Cumulatively, the company has distributed 353 million yuan in dividends since its A-share listing [3]. Shareholder Structure - As of September 19, the number of shareholders for Xiaofang Pharmaceutical was 13,500, a decrease of 8.81% from the previous period. The average number of circulating shares per shareholder increased by 49.14% to 4,031 shares [2]. - Notable changes in institutional holdings include new entries from CITIC Jiantou Rotation Mixed A and CITIC Jiantou Selection Mixed A, which are now among the top five shareholders [3].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海小方制药股份有限公司（以下简称"公司"）于2024年10月15日分别召开第一届 董事会第十八次会议、第一届监事会第十一次会议，审议通过了《上海小方制药股份有限 公司关于使用部分暂时闲置募集资金进行现金管理的议案》，同意公司在保证不影响募集 资金投资计划正常进行以及确保资金安全的前提下，拟使用不超过人民币200,000,000元（ 含本数）的闲置募集资金进行现金管理，用于购买期限最长不超过12个月的安全性高、流 动性好、满足保本要求的银行存款类产品（包括但不限于协定性存款、定期存款、大额存 单等）。保荐机构对本事项出具了明确无异议的专项核查意见。具体内容详见公司于2024 年10月16日在上海证券交易所网站（www.sse.com.cn）披露的《关于使用部分暂时闲置募集 资金进行现金管理的公告》（公告编号：2024010）。 一、募集资金现金管理到期赎回情况 截至本公告披露日，公司已全部赎回本次用于现金管理的闲置募集资金，本金及收益均 已归还至募集资金专户，具体情况如下： 币种 ...

证券代码：603207 证券简称：小方制药 公告编号：2025-035 上海小方制药股份有限公司2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.70元 相关日期 经公司 2025 年 8 月 22 日召开的第二届董事会第五次会议审议通过了《关于上海小方制 药股份有限公司 2025 年中期利润分配方案的议案》。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本160,559,967股为基数，每股派发现金红利0.70 元（含税），共计派发现金红利112,391,976.90元。 1. 发放年度：2025年半年度 2. 分派对象： | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | ...

Core Viewpoint - Shanghai Xiaofang Pharmaceutical Co., Ltd. has signed a technical entrustment contract with Boji Pharmaceutical Technology Co., Ltd. to assist in the clinical research and registration of the new traditional Chinese medicine "Compound Cèbǎi Tincture" for hair loss treatment, marking a significant step in the company's innovation drug strategy [2][12]. Group 1: Transaction Overview - The transaction does not constitute a major asset restructuring as defined by the relevant regulations and does not involve related party transactions [2]. - The collaboration aims to complete the clinical trials and market registration of the new drug, with no significant impact on the company's operating results for the current year [3][12]. Group 2: Partner Information - Boji Pharmaceutical, established in 2002 and listed on the Shenzhen Stock Exchange in 2015, specializes in providing comprehensive outsourcing services for drug and medical device development [4]. - The company has a registered capital of 381.99 million RMB and has a strong track record in traditional Chinese medicine research and development [4]. Group 3: Project Details - The project involves the development of the traditional Chinese medicine "Compound Cèbǎi Tincture" through a commissioned development approach [5]. - Boji Pharmaceutical is responsible for designing and executing the research plans, conducting clinical trial monitoring, and assisting in the registration application [7]. Group 4: Contractual Terms - The intellectual property generated from the project will belong to Shanghai Xiaofang Pharmaceutical, including clinical trial data and research reports [6]. - The contract will be effective upon signing and will remain valid until the new drug application (NDA) is approved [9]. Group 5: Impact on the Company - The collaboration is expected to leverage the strengths of both companies, enhancing the efficiency and success rate of the product's development, thereby laying a solid foundation for future applications and market entry [12].

Core Viewpoint - The collaboration between Xiaofang Pharmaceutical and Boji Pharmaceutical Technology Co., Ltd. aims to enhance the clinical research and registration of a new traditional Chinese medicine product, thereby improving the efficiency and success rate of the development process [1] Group 1: Company Collaboration - Xiaofang Pharmaceutical has signed a technology entrustment contract with Boji Pharmaceutical to assist in the clinical research and registration of a Class 1 compound medicine [1] - Boji Pharmaceutical is recognized as an industry leader with significant advantages in research and development capabilities, technical accumulation, and clinical resources [1] - The partnership is expected to leverage the strengths of both companies, creating a synergistic effect that will solidify the foundation for subsequent product application and market launch [1]

证券代码：603207 证券简称：小方制药 公告编号：2025-034 上海小方制药股份有限公司 关于委托博济医药技术开发中药1.1类新药 公司名称：博济医药科技股份有限公司 统一社会信用代码：91440101743555883K 法定代表人：王廷春 "复方侧柏酊"（脱发适应症）的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 事项概述：上海小方制药股份有限公司（以下简称"公司"）近日与博济医 药科技股份有限公司（以下简称"博济医药"）签署了《技术委托（开发）合同》， 博济医药将协助公司完成中药 1.1 类复方侧柏酊新药临床研究及注册，推动其完成 临床试验及上市。 本次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组， 亦不构成关联交易。 本次交易对公司本年度经营成果无重大影响。 前期，公司与上海市皮肤病医院签署了《复方侧柏酊合作开发协议》，双方拟共 同开展复方侧柏酊的新药转化开发，具体内容详见公司于 2025 年 6 月 13 日披露的《 关于自愿披露与上海皮肤病医院合作开发治疗脱发中药 1.1 类新药复方侧柏酊的公告》 （公告 ...